A Northern California Oncology Group Randomized Trial of Single Agent 5-FU vs. High-Dose Folinic Acid + 5-FU vs. Methotrexate + 5-FU + Folinic Acid in Patients with Disseminated Measurable Large Bowel Cancer
Numerous Phase II and Phase III trials have demonstrated that combinations of folinic acid plus 5-FU or sequential methotrexate, 5-FU, folinic acid are effective treatments for patients with advanced carcinoma of the colon or rectum (1–10). In many of these studies the objective response rates in previously untreated patients were greater than 30%. These rates are in excess of those expected for treatment with 5-FU alone (11) suggesting that these combinations are more effective than 5-FU for treatment of patients with advanced colorectal carcinomas.
KeywordsEvaluable Patient Hematologic Toxicity Objective Response Rate Karnofsky Performance Status Folinic Acid
Unable to display preview. Download preview PDF.
- 1.D. Machover, E. Goldschmit, P. Chollet, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid, JL Clin. Oncol. 4: 685–698, (1986).Google Scholar
- 2.P. Bryne, F. Smith, M.W. Treat, et al: 5-Fluorouracil and higher dose folinic acid treatment of colorectal carcinoma patients, Proc. ASCO 2: 121, (1983).Google Scholar
- 4.J.D. Hines, M.H. Zakem, D.J. Adelstein, et al., Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: A pilot study, a. Clin. Oncol. 6: 142–146, (1988).Google Scholar
- 5.C. Erlichman, S. Fine, A. Wong, et al., A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma, 2. Clin. Oncol. 6: 469–475, (1988).Google Scholar
- 7.R. Hermann, J. Spehn, J.H. Beyer, et al: Sequential methotrexate and 5-fluorouracil: Improved response rate in metastatic colorectal cancer, a. Clin. Oncol. 2: 591–594, (1984).Google Scholar
- 8.N.E. Kemeny, T. Ahmed, R.A. Michaelson, et al., Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: Attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate, 2. Clin. Oncol., 2: 311–315, (1984).Google Scholar
- 9.B.A. Leone, A. Romero, M.G. Rabinovich, et al., Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma, 2. Clin. Oncol., 4: 23–27, (1986).Google Scholar
- 10.R.J. Ignoffo, M.A. Friedman, M. Gribble, et al., Phase II study of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: Northern California Oncology Group Study, Cancer Treat. Rep. 68: 983–988, (1984).Google Scholar
- 11.C.G. Moertel, Chemotherapy of gastrointestinal cancer. New Engl. J. Med. 299: 1049, (1978).Google Scholar
- 12.F.H. Valone, M. Kohler, K. Fisher, et al, A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone, NCI Monographs 5: 175–177, (1987).PubMedGoogle Scholar
- 13.W. Hryiuk, The impact of dose intensity on the design of clinical trials, Seminars Oncol. 14: 65–74, (1987).Google Scholar